Drug Type Antibody drug conjugate (ADC) |
Synonyms AntiCD19 antibodySN38 antibodydrug conjugate Immunomedics, hA19SN38 ADC Immunomedics |
Target |
Action modulators, inhibitors |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingDiscovery |
First Approval Date- |
Regulation- |
Molecular FormulaC22H20N2O5 |
InChIKeyFJHBVJOVLFPMQE-QFIPXVFZSA-N |
CAS Registry86639-52-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Leukemia | Discovery | United States | 15 Nov 2016 |